⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Velsera and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Velsera
↗Boston, USA
Velsera is a global precision medicine technology company formed in 2023 through the merger of Seven Bridges, Pierian, and UgenTec. The company provides a universal software platform that connects clinical care with research and development, aiming to accelerate the discovery, development, and delivery of precision medicine.
Velsera's offerings include advanced data platforms, analytics, and expert services for multimodal data analysis, clinical NGS reporting, and drug discovery workflows. In 2025, the company launched its Global Data Network (GDN), which connects over 175 million patient records to facilitate real-world, longitudinal clinicogenomic data access for life sciences and healthcare organizations.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:
Industry:Digital Health
Sub-Industry:Bioinformatics / Precision Medicine
SIZE & FINANCIALS
Employees:501-1000
Founded:2023
Ownership:private
Status:operating
FUNDING
Stage:Private Equity
Investors:Summa Equity
0
CORPORATE STRUCTURE
Subsidiaries:Seven Bridges, Pierian, UgenTec
Key Partnerships:Complete Genomics (Integration of sequencing and analysis platforms)
COMPETITION
Position:Emerging
Competitors:485 active competitors identified by market intelligence
LEADERSHIP
Key Executives:
Jamie Littlejohns - CEO
Rakesh Nagarajan - Chief Medical Officer
LINKS
Website:velsera.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Velsera. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.